SEC Form 4 · accession 0001209191-19-014072
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — Chief Executive Officer · Director
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2019 | M | 17,000 | $0.78 | A | 135,700 | D | |
| Common Stock | Feb 25, 2019 | S | 17,000 | $30.00 | D | 118,700 | D | |
| Common Stock | Feb 25, 2019 | M | 4,000 | $2.19 | A | 122,700 | D | |
| Common Stock | Feb 25, 2019 | S | 4,000 | $30.00 | D | 118,700 | D | |
| Common StockF2 | holding | — | — | — | 171,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F3 | $0.78 | Feb 25, 2019 | M | 17,000 | D | — | Sep 25, 2023 | Common Stock | 17,000 | 64,751 | D |
| Stock Option (right to buy)F4,F5 | $2.19 | Feb 25, 2019 | M | 4,000 | D | — | Feb 4, 2025 | Common Stock | 4,000 | 74,297 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F3The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.
- F4The exercise of 26,901 options on July 3, 2018 and 23,147 options on July 5, 2018, each having an exercise price of $2.19 per share, were previously reported on Form 4 filed on July 5, 2018 as having an exercise price of $0.78. This Form 4 reflects the correct number of options attributed to each grant and beneficially owned following the transactions reported in this Form 4.
- F5The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.